Emerging drugs for the treatment of noninfectious uveitis

References

• de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011 Nov;30(6):452–470. PubMed PMID: 21807112.
   PubMed Web of Science ®Google Scholar
• Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the pacific ocular inflammation study. JAMA Ophthalmol. 2013 Nov;131(11):1405–1412. PubMed PMID: 24008391.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Foliato G, Modorati G, et al. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013 Sep-Oct;23(5):705–717. PubMed PMID: 23661536.
   PubMed Web of Science ®Google Scholar
• Berlinberg EJ, Gonzales JA, Doan T, et al. Association between noninfectious uveitis and psychological stress. JAMA Ophthalmol. 2019;137(2):199–205. PubMEd PMID: 30520957.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005 Sep;140:509–516. PubMed PMID: 16196117.
   PubMed Web of Science ®Google Scholar
• Forrester JV, Kuffova L, Dick AD. Autoimmunity, Autoinflammation, and Infection in Uveitis. Am J Ophthalmol. 2018 May;189:77–85. PubMed PMID: 29505775.
   PubMed Web of Science ®Google Scholar
• Niemeyer KM, Gonzales J, Doan T, et al. Time trade-off utility values in noninfectious uveitis. Am J Ophthalmol. 2019 Jun 12. pii: S0002-9394(19)30272-7. PubMed PMID: 31201795.
   PubMed Web of Science ®Google Scholar
• Benezra D, Cohen E. Treatment and visual prognosis in Behçet’s disease. Br J Ophthalmol. 1986 Aug;70(8):589–592. PubMed PMID: 3741823.
   PubMed Web of Science ®Google Scholar
• Diwo E, Sève P, Trad S, et al. Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel. Rev Med Interne. 2018 Sep;39(9):687–698. PubMed PMID: 29610003.
   PubMed Web of Science ®Google Scholar
• Gallego-Pinazo R, Dolz-Marco R, Martinez-Castillo S, et al. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets. 2013 Feb;12(1):38–45. PubMed PMID: 23441991.
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000 Oct;130(4):492–513. PubMed PMID: 11024423.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Ozurdex HURON study group: dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545–553. PubMed PMID: 21220619.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014 Aug;121(8):1649–1654. PubMed PMID: 24650556.
   PubMed Web of Science ®Google Scholar
• Pohlmann D, Vom Brocke GA, Winterhalter S, et al. Dexamethasone inserts in noninfectious uveitis: a single-center experience. Ophthalmology. 2018 Jul;125(7):1088–1099. PubMed PMID: 29459041.
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158(6):1136e1145. PubMed PMID: 25217856.
   Web of Science ®Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191–1201. PubMed PMID: 18779477.
   PubMedGoogle Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide uveitis study group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006 June;113(6):1020–1027. PubMed PMID: 16690128.
   PubMed Web of Science ®Google Scholar
• Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic antiinflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–1926. PubMed PMID: 21840602.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132. Pubmed PMID: 22727177.
   PubMed Web of Science ®Google Scholar
• Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008 Mar;92(3):383–388. PubMed PMID: 18303160.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina. 2013 Nov-Dec;33(10):2149–2154. PubMed PMID: 23615343.
   PubMed Web of Science ®Google Scholar
• Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol. 2005 Jun;89(6):666–669. PubMed PMID: 15923497.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE study. J Ophthalmic Inflamm Infect. 2013;3(1):32–38. PubMed: PMID: 23514595.
   PubMedGoogle Scholar
• Gilger BC, Wilkie DA, Clode AB, et al. Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Vet Ophthalmol. 2010;13(5):294–300. PMID: 20840106.
   PubMed Web of Science ®Google Scholar
• Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther. 2012 Dec;28(6):628–631. PubMed PMID: 22794354.
   PubMed Web of Science ®Google Scholar
• Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010 Aug;117(8):1612–1616. PubMed PMID: 20378179.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye disease: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) cohort study. Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):47–55. PubMed PMID: 18300089.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort series. BMJ. 2009 Jul;339:b2480. PubMed PMID: 19578087.
   PubMedGoogle Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–2198. PubMed PMID: 19748676.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009 Oct;148(4):500–509.e2. PubMed PMID: 19570522.
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010 Mar;149(3):423–432. PubMed PMID: 20042178.
   PubMed Web of Science ®Google Scholar
• Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010 Mar;117(3):576–584. PubMed PMID: 20031223.
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010 Feb;117(2):356–365. PubMed PMID: 19969366.
   PubMed Web of Science ®Google Scholar
• Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004 Apr;31(4):645–648. PubMed PMID: 15088287.
   PubMed Web of Science ®Google Scholar
• Bianchi D, Caporalo R, Todoerti M, et al. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oralroutes of administration. Adv Ther. 2016 Mar;33(3):369–378. PubMed PMID: 26846283.
   PubMed Web of Science ®Google Scholar
• Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004 Mar;43(3):267–271. PubMed PMID:14963199.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006 Jun;11(6):694–703. PubMed PMID: 16794248.
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic non-infectious uveitis. Analysis of a case series of 160 patients. Ophthalmology. 2001;108(6):1134–1139. PubMed PMID: 11382642.
   PubMed Web of Science ®Google Scholar
• Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systemic review and meta-analysis approach. Rheumatology (Oxford). 2013;52(5):825–831. PubMed PMID: 22879466.
   PubMed Web of Science ®Google Scholar
• Papadopoulou C, Kostik M, Böhm M, et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013 Sep;163(3):879–884. PMID: 23664559.
   PubMed Web of Science ®Google Scholar
• Lee K, Bajwa A, Freitas-Neto CA, et al. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. Expert Opin Pharmacother. 2014 Oct;15(15):2141–2154. PMID: 25226529.
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG, et al. A con-trolled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990 Feb;322(5):281–285. PMID: 2404204.
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008 Oct;115(10):1826–1832. PubMed PMID: 18579209.
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000 May;47(2–3):85–118. PubMed PMID: 10878285.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014 Oct;121(10):1863–1870. PubMed PMID: 24917273.
   PubMed Web of Science ®Google Scholar
• Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011 Jun;16(2):309–322. PubMed PMID: 21210752.
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet. 1989 May;1(8647):1093–1096. PubMed PMID: 2566048.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991 Aug;112(2):138–146. PubMed PMID: 1867297.
   PubMed Web of Science ®Google Scholar
• Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol. 2010 Jan-Feb;58(1):55–58. PubMed PMID: 20029146.
   PubMed Web of Science ®Google Scholar
• Wakefield D, McCluskey P, Wildner G, et al. Inflammatory eye disease: pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: recommendations from an expert committee. Autoimmun Rev. 2017 Mar;16(3):213–222. PubMed PMID: 28137477.
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007 May;114(5):1000–1006. PubMed PMID: 17467532.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005 May;123(5):634–641. PMID:15883282.
   PubMedGoogle Scholar
• Leung TG, Thorne JE. Emerging drugs for the treatment of uveitis. Expert Opin Emerg Drugs. 2013 Dec;18(4):513–521. PubMed PMID: 24274613.
   PubMed Web of Science ®Google Scholar
• Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol. 1992 Apr;76(4):241–243. PubMed PMID: 1390495.
   PubMed Web of Science ®Google Scholar
• Suelves AM, Arcinue CA, González-Martín JM, et al. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. Ophthalmology. 2013 Jun;120(6):1201–1209. Pubmed PMID: 23601800.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002 Feb;109(2):370–377. PubMed PMID: 11825825.
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST, Ringold S, Beukelman T, et al. American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol. 2019 Jun;71(6):864–877. Pubmed PMID: 31021511.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018 Jun;77(6):808–818. Pubmed PMID: 29625968.
   PubMed Web of Science ®Google Scholar
• Urruticechea-Arana A, Cobo-Ibánez T, Villaverde-Garcia V, et al. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review. Rheumatol Int. 2019 Jan;39(1):47–58. PubMed PMID: 30421105.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016 Sep 8;375(10):932–943. PubMed PMID: 27602665.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep;388(10050):1183–1192. PubMed PMID: 27542302.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Thorne JE, Mittal M, et al. Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis: post hoc analyses from the VISUAL-1 and VISUAL-2 trials. Ophthalmology. 2017 Dec;124(12):1799–1807. PubMed PMID: 28689898.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adan A, Brezin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018 Jul;125(7):1075–1087. PMID: 29429764.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376:1637–1646. Pub Med PMID: 28445659.
   PubMed Web of Science ®Google Scholar
• Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018 Jul;77(7):1003–1011. PubMed PMID: 29275333.
   PubMed Web of Science ®Google Scholar
• Bitossi A, Bettiol A, Silvestri E, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediators Inflamm. 2019;2019:1623847. PubMed PMID: 30881221.
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Scarpati LM, et al. The burden of non-infectious intraocular inflammatory eye diseases: a systematic literature review. Curr Med Res Opin. 2018 Dec;34(12):2095–2103. PubMed PMID: 30112931.
   PubMed Web of Science ®Google Scholar
• Chu DS, Johnson SJ, Mallya UG, et al. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect. 2013 Nov 6;3(1):64. PubMed PMID: 24195808.
   PubMedGoogle Scholar
• Thorne JE, Skup M, Tundia N, et al. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol. 2016 Aug;94(5):e331–9. PubMed PMID: 26932535.
   PubMed Web of Science ®Google Scholar
• Adán-Civera AM, Benítez-Del-Castillo JM, Blanco-Alonso R, et al. Burden and direct costs of non infectious uveitis in Spain. Reumatol Clin. 2016 Jul-Aug;12(4):196–200. PubMed PMID: 26490513.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorence V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014 Dec;121(12):2380–2386. PubMed PMID: 25204610.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017 Apr;25(2):215–220. PuMed PMID: 26731514.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorence V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018 Jul;38(7):1361–1370. PubMed PMID: 28520640.
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Calco-Río V, Mesquida M, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85–94. PuMed PMID: 30660771.
   PubMed Web of Science ®Google Scholar
• Denniston AK, Keane PA, Srivastava SK. Biomarkers and Surrogate Endpoints in Uveitis: the Impact of Quantitative Imaging. Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO131–BIO140. PubMed PMID: 28655060.
   PubMed Web of Science ®Google Scholar
• Caspi RR. A look at autoimmunity and inflammation in the eye. J Clin Invest. 2010 Sep;120(9):3073–3083. PubMed PMID: 20811163.
   PubMed Web of Science ®Google Scholar
• Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008 Apr;205(4):799–810. PubMed PMID: 18391061.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorence V, et al. Targeting interleukin-6 in autoimmune uveitis. Autoimmun Rev. 2017 Oct;16(10):1079–1089. PubMed PMID: 28778705.
   PubMed Web of Science ®Google Scholar
• Lin P. Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015;9:1697–1702. PubMed PMID: 26392750.
   PubMed Web of Science ®Google Scholar
• Mudumba S, Bezwada P, Takanaga H, et al. Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocul Pharmacol Ther. 2012 Oct;28(5):507–514. PubMed PMID: 22662868.
   PubMed Web of Science ®Google Scholar
• Dietrichs-Möhring M, Niesik S, Priglinger CS, et al. Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells. J Neuroinflammation. 2018 Feb;15(1):54. PubMed PMID: 29467002.
   PubMedGoogle Scholar
• Dietrichs-Möhring M, Leban J, Strobl S. A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2014 Dec;56(2):1147–1157. PubMed PMID: 25515581.
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001 Sep-Oct;33(5):251–255. PubMed PMID: 11586057.
   PubMed Web of Science ®Google Scholar
• Borras-Blasco J, Castera DE, Cortes X, et al. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults. Int J Clin Pharmacol Ther. 2015 May;53(5):377–390.11. PubMed PMID: 25345430.
   PubMed Web of Science ®Google Scholar
• Lie E, Lindstrom U, Zverkova-Sandstrom T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017 Sep;76(9):1515–1521. PubMed PMID: 28254789.
   PubMed Web of Science ®Google Scholar
• Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503–510. PMID:21862108.
   PubMed Web of Science ®Google Scholar
• Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228–233. PubMed PMID: 29030361.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018 Sep;70(9):1399–1407. PubMed PMID: 29623679.
   PubMed Web of Science ®Google Scholar
• Tosi GM, Sota J, Vitale A, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019;37(4):680–683. PubMed PMID: 30943133.
   PubMed Web of Science ®Google Scholar
• Llorenc V, Mesquida M, Sainz de la Maza M, et al. Certolizumab Pegol, a New Anti-TNF-alpha in the Armamentarium against. Ocul Immunol Inflamm. 2016;24(2):167–172. PubMed PMID: 25325834.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol. 2017;27(6):1031–1035. PubMed PMID: 28712320.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the french uveitis network. Arthritis Rheumatol. 2016;68(6):1522–1530. PubMed PMID: 27015607.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol. 2018;37(10):2805–2809. PubMed PMID: 29766375.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407–415. PubMed PMID: 30099655.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Blanco R, Santos-Gomez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95–101. PubMed PMID: 27060872.
   PubMed Web of Science ®Google Scholar
• van Bentum RE, Heslinga SC, Nurmohamed MT, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab – the GO-EASY study. J Rheumatol. 2019;46(2):153–159. PubMed PMID: 30385705.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behcet’s Disease. Ocul Immunol Inflamm. 2019;27(1):58–63. PubMed PMID: 28981395.
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437–440. PubMed PMID: 12695239.
   PubMed Web of Science ®Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007 Oct;56(10):3248–3252. PubMed PMID: 17907169.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80. PubMed PMID: 28887113.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-Interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69(3):668–675. PubMed PMID: 27696756.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2:4. PubMed PMID: 30886955.
   PubMedGoogle Scholar
• Tode J, Richert E, Koinzer S, et al. Intravitreal injection of anti-Interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice. Cytokine. 2017;96:8–15. PubMed PMID: 28267649.
   PubMed Web of Science ®Google Scholar
• Heissigerova J, Callanan D, de Smet MD, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2019;126(3):428–437. PubMed PMID: 30316888.
   PubMed Web of Science ®Google Scholar
• Baerveldt EM, Kappen JH, Thio HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behcet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72(4):626–627. PubMed PMID: 23148307.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Del Piano M, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017 Sept;30(5):e12527. PubMed PMID: 28833973.
   PubMed Web of Science ®Google Scholar
• Mirouse A, Barete S, Monfort JB, et al. Ustekinumab for Behcet’s disease. J Autoimmun. 2017;82:41–46. PubMed PMID: 28483439.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. PuMed PMID: 20926833.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787. PubMed PMID: 23290985.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939–948. PubMed PMID:25638011.
   PubMed Web of Science ®Google Scholar
• Wan CK, He C, Sun L, et al. Cutting edge: IL-1 receptor signaling is critical for the development of autoimmune uveitis. J Iimmunol. 2016;196(2):543–546. PubMed PMID: 26643477.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293–1301. PubMed PMID: 24305945.
   PubMed Web of Science ®Google Scholar
• Brambilla A, Caputo R, Cimaz R, et al. Canakinumab for childhood sight-threatening refractory uveitis: a case series. J Rheumatol. 2016;43(7):1445–1447. PubMed PMID: 27371650.
   PubMed Web of Science ®Google Scholar
• Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563–566. PubMed PMID: 22084392.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun IM, Kadayifcilar SM, Khairallah MM, et al. Safety and efficacy of gevokizumab in patients with behcet’s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2017;25(1):62–70. PubMed PMID: 26829647.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023–1033. PubMed PMID: 29370572.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 1999;96(13):7462–7466. PubMed PMID: 10377437.
   PubMed Web of Science ®Google Scholar
• Wroblewski K, Sen HN, Yeh S, et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol. 2011;46(4):322–328. PubMed PMID: 21816251.
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflamm. 2007 Mar-Apr;15(2):63–70. PMID: 17558830.
   PubMed Web of Science ®Google Scholar
• Lasave AF, You C, Ma L, et al. Long-term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy. Retina. 2018;38(2):395–402. PubMed PMID: 28225369.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782–786. PubMed PMID: 26396026.
   PubMed Web of Science ®Google Scholar
• Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(6):821–825. PubMed PMID: 20191477.
   PubMed Web of Science ®Google Scholar
• Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. J Rheumatol. 2016;43(11):2068–2073. PubMed PMID: 27633826.
   PubMed Web of Science ®Google Scholar
• Tsambaos E, Eichelberg D, Goos M. Behçet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res. 1986;278(4):335–336.
   PubMed Web of Science ®Google Scholar
• Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35(5):896–903. Pubmed PMID: 18412306.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-treatment in patients with severe uveitis due to Behçet´s disease. Arthritis Rheum. 2010;62:2796–2805. Pubmed PMID: 20518075.
   PubMed Web of Science ®Google Scholar
• Yalçindag N, Köse HC. Comparison of the treatment results for Behçet uveitis in patients treated with infliximab and interferon. Ocul Immunol Inflamm. 2019;3:1–10. Pubmed MID: 31268743.
   Google Scholar
• De Simone L, Sangiovanni A, Aldigeri R, et al. Interferon alpha-2a treatment for post-uveitic refractory macular edema. Ocul Immunol Inflamm. 2019;20:1–7. PMID: 31107604.
   Google Scholar
• Komaki Y, Yamada A, Komaki F, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-alpha agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017;79:4–16. PubMed PMID: 28209290.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet’s disease after switching from infliximab originator. Eur J Rheumatol. 2017;4(4):288–290. PubMed PMID: 29308287.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Venerito V, Cantarini L, et al. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behcet’s disease. Intern Emerg Med. 2019 Aug;14(5):719–722. Pubmed PMID: 30361849.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013 Feb;72(2):165–178. Pubmed PMID: 23178294.
   PubMed Web of Science ®Google Scholar
• Grossi V, Gulli F, Infantino M, et al. The laboratory role in anti-TNF biological therapy era. Immunol Invest. 2019 Jul 12:1–16. Pubmed PMID: 31298595.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Calleja-Antolin S, Garzo-Garcia I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology. 2016 Dec;123(12):2618–2625. PMID: 27692527.
   PubMed Web of Science ®Google Scholar
• Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019;104(3):246–250. PMID: 30026253.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Raychaudhuri SP. Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis. Curr Opin Rheumatol. 2017 Jul;29(4):311–316. PubMed PMID: 28394822.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug;367(6):495–507. PubMed PMID: 22873530.
   PubMed Web of Science ®Google Scholar
• Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018;13:53–55. PubMed PMID: 30582071.
   PubMedGoogle Scholar
• Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72(9):1475–1480. PubMed PMID: 22984171.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet’s syndrome – a phase 2, placebo-controlled study. N Eng J Med. 2015;372(16):1510–1518. PubMed PMID:25875256.
   PubMed Web of Science ®Google Scholar
• Leal I, Rodrigues FB, Sousa DC, et al. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis – a systematic review. Acta Ophthalmol. 2018;96(6):e665–e675. Pubmed PMID: 29577629.
   PubMed Web of Science ®Google Scholar